Status:
COMPLETED
Study to Evaluate QLS-101 Compared to Timolol Maleate Eye Drops in Subjects With High Eye Pressure (Glaucoma or Ocular Hypertension).
Lead Sponsor:
Qlaris Bio, Inc.
Conditions:
Primary Open Angle Glaucoma
Ocular Hypertension
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
Evaluating the safety and tolerability of QLS-101 versus timolol maleate ophthalmic solution in glaucoma or ocular hypertension.
Detailed Description
Multi-site study to evaluate the safety and tolerability of 3 concentrations of QLS-101 versus timolol maleate Preservative Free (PF) 0.5% ophthalmic solution in subjects with primary open-angle glauc...
Eligibility Criteria
Inclusion
- Visual acuity +1.0 logMAR or better
- Willing to give informed consent
- Ability to washout from current intraocular pressure lowering medications -
Exclusion
- Severe glaucomatous damage
- Previous glaucoma intraocular or laser surgery
- Refractive surgery
- Ocular infection or inflammation
Key Trial Info
Start Date :
March 31 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 17 2022
Estimated Enrollment :
84 Patients enrolled
Trial Details
Trial ID
NCT04830397
Start Date
March 31 2021
End Date
February 17 2022
Last Update
January 17 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Dixon Eye Care
Albany, Georgia, United States, 31701